NASDAQ · AVTX
Healthcare · Biotechnology
$7.25
Down-$0.25 (-3.38%)
Updated Nov 4, 2026, 5:42 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AVTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
AVTX closed at $7.25 after 21 trading sessions, down 46.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $7.42 | $7.625 | $7.05 | $7.25 | 1.83M |
| Nov 2, 2026 | $7.13 | $7.46 | $7.0001 | $7.32 | 1.62M |
| Oct 30, 2026 | $7.38 | $7.47 | $7.05 | $7.17 | 1.53M |
| Oct 29, 2026 | $7.18 | $7.708 | $7.18 | $7.44 | 2.27M |
| Oct 28, 2026 | $6.66 | $7.145 | $6.66 | $7.12 | 2.17M |
| Oct 27, 2026 | $6.91 | $6.98 | $6.58 | $6.75 | 2.64M |
| Oct 26, 2026 | $6.82 | $7.13 | $6.56 | $6.77 | 2.37M |
| Oct 23, 2026 | $7.27 | $7.50 | $6.53 | $6.93 | 4.55M |
| Oct 22, 2026 | $8.99 | $9.35 | $6.85 | $7.45 | 26.19M |
| Oct 21, 2026 | $12.41 | $13.18 | $12.22 | $12.26 | 930.22K |
| Oct 20, 2026 | $11.61 | $12.8516 | $11.26 | $12.36 | 1.87M |
| Oct 19, 2026 | $11.37 | $11.96 | $11.21 | $11.59 | 2.22M |
| Oct 16, 2026 | $12.05 | $12.05 | $11.23 | $11.27 | 971.1K |
| Oct 15, 2026 | $11.93 | $12.345 | $11.70 | $12.01 | 936.29K |
| Oct 14, 2026 | $11.90 | $12.12 | $11.58 | $11.84 | 1.24M |
| Oct 13, 2026 | $13.23 | $13.23 | $11.99 | $12.01 | 1.65M |
| Oct 12, 2026 | $13.56 | $13.69 | $13.13 | $13.24 | 502.77K |
| Oct 9, 2026 | $13.42 | $13.82 | $13.355 | $13.65 | 648.58K |
| Oct 8, 2026 | $13.45 | $13.60 | $12.77 | $13.43 | 990.41K |
| Oct 7, 2026 | $13.43 | $13.98 | $13.30 | $13.58 | 719.03K |
| Oct 6, 2026 | $14.58 | $14.581 | $13.23 | $13.59 | 955.58K |
The latest Smart Investors Daily articles mentioning AVTX.
Company
Market Activity
Research & News
AVTX research
Company profile and research snapshot.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | Wedbush | Outperform | — |
| Oct 23, 2026 | HC Wainwright & Co. | Neutral | — |
| Oct 23, 2026 | Guggenheim | Neutral | — |
| Oct 23, 2026 | BTIG | Buy | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 25, 2026
Avalo's positive LOTUS results now support a pivotal trial, and its monthly dosing gives it a potential differentiating factor in HS. Read why AVTX stock is a Buy.
Benzinga · Oct 23, 2026
Guggenheim analyst Yatin Suneja downgrades Avalo Therapeutics (NASDAQ:AVTX) from Buy to Neutral.
Benzinga · Oct 23, 2026
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.
Benzinga · Oct 23, 2026
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Avalo Therapeutics (NASDAQ:AVTX) from Buy to Neutral.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVTX.
